title: Taxol extravasation: a case report.
abstract: Taxol is a relatively new antineoplastic agent whose classification as either vesicant, non-vesicant, or irritant remains under debate. This case study is presented to follow a large-volume Taxol extravasation. The article illustrates assessment, follow-up, intervention and outcome of this situation. This case suggests the drug is a vesicant with the potential to cause moderate soft tissue injury.
authors.affiliation: Toronto Hospital, Ontario.
authors.forename: W L
authors.initials: WL
authors.lastname: Bailey
authors.forename: R M
authors.initials: RM
authors.lastname: Crump
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000451:nursing*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel